Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

NCT06783153 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Radiotherapy Induced Diarrhea
Acute Radiation Enteritis
Prostate Cancer
Cervical Adenocarcinoma
Bladder (Urothelial, Transitional Cell) Cancer
Rectal Adenocarcinoma
Pelvic Radiotherapy
Rifaximin

Interventions

DRUG: Rifaximin 550 MG
DRUG: Standard Care Chemoradiation

Sponsor

Mansoura University